Sign In
NASDAQ:AXGN
AxoGen Stock Earnings Reports
$17.25
+0.0900 (+0.524%)
At Close: Mar 14, 2025
AxoGen Earnings Calls
Q4 2024
Beat
$0.0800 (100.00%)
| Release date | Feb 25, 2025 |
| EPS estimate | $0.0400 |
| EPS actual | $0.0800 |
| EPS Surprise | 100.00% |
| Revenue estimate | 48.28M |
| Revenue actual | 49.405M |
| Revenue Surprise | 2.33% |
Q3 2024
Beat
$0.0700 (1,066.67%)
| Release date | Nov 07, 2024 |
| EPS estimate | $0.0060 |
| EPS actual | $0.0700 |
| EPS Surprise | 1,066.67% |
| Revenue estimate | 47.445M |
| Revenue actual | 48.644M |
| Revenue Surprise | 2.53% |
Q2 2024
Beat
$0.0500 (200.00%)
| Release date | Aug 08, 2024 |
| EPS estimate | -$0.0500 |
| EPS actual | $0.0500 |
| EPS Surprise | 200.00% |
| Revenue estimate | 43.39M |
| Revenue actual | 47.912M |
| Revenue Surprise | 10.42% |
Q1 2024
Beat
-$0.0600 (40.00%)
| Release date | May 02, 2024 |
| EPS estimate | -$0.100 |
| EPS actual | -$0.0600 |
| EPS Surprise | 40.00% |
| Revenue estimate | 43.39M |
| Revenue actual | 41.378M |
| Revenue Surprise | -4.64% |
Last 4 Quarters for AxoGen
Below you can see how AXGN performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q1 2024
Beat
| Release date | May 02, 2024 |
| Fiscal end date | Mar 31, 2024 |
| Price on release | $5.88 |
| EPS estimate | -$0.100 |
| EPS actual | -$0.0600 |
| EPS surprise | 40.00% |
| Date | Price |
|---|---|
| Apr 26, 2024 | $6.63 |
| Apr 29, 2024 | $6.66 |
| Apr 30, 2024 | $6.41 |
| May 01, 2024 | $6.56 |
| May 02, 2024 | $5.88 |
| May 03, 2024 | $5.79 |
| May 06, 2024 | $5.67 |
| May 07, 2024 | $5.83 |
| May 08, 2024 | $5.87 |
| 4 days before | -11.31% |
| 4 days after | -0.170% |
| On release day | -1.53% |
| Change in period | -11.46% |
Q2 2024
Beat
| Release date | Aug 08, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $10.70 |
| EPS estimate | -$0.0500 |
| EPS actual | $0.0500 |
| EPS surprise | 200.00% |
| Date | Price |
|---|---|
| Aug 02, 2024 | $8.10 |
| Aug 05, 2024 | $7.80 |
| Aug 06, 2024 | $7.83 |
| Aug 07, 2024 | $7.92 |
| Aug 08, 2024 | $10.70 |
| Aug 09, 2024 | $11.02 |
| Aug 12, 2024 | $10.87 |
| Aug 13, 2024 | $11.26 |
| Aug 14, 2024 | $10.75 |
| 4 days before | 32.10% |
| 4 days after | 0.467% |
| On release day | 2.99% |
| Change in period | 32.72% |
Q3 2024
Beat
| Release date | Nov 07, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $13.27 |
| EPS estimate | $0.0060 |
| EPS actual | $0.0700 |
| EPS surprise | 1,066.67% |
| Date | Price |
|---|---|
| Nov 01, 2024 | $13.95 |
| Nov 04, 2024 | $14.20 |
| Nov 05, 2024 | $14.96 |
| Nov 06, 2024 | $15.33 |
| Nov 07, 2024 | $13.27 |
| Nov 08, 2024 | $12.66 |
| Nov 11, 2024 | $13.97 |
| Nov 12, 2024 | $13.27 |
| Nov 13, 2024 | $12.54 |
| 4 days before | -4.87% |
| 4 days after | -5.50% |
| On release day | -4.60% |
| Change in period | -10.11% |
Q4 2024
Beat
| Release date | Feb 25, 2025 |
| Fiscal end date | Dec 31, 2024 |
| Price on release | $20.11 |
| EPS estimate | $0.0400 |
| EPS actual | $0.0800 |
| EPS surprise | 100.00% |
| Date | Price |
|---|---|
| Feb 19, 2025 | $18.68 |
| Feb 20, 2025 | $18.50 |
| Feb 21, 2025 | $18.00 |
| Feb 24, 2025 | $18.01 |
| Feb 25, 2025 | $20.11 |
| Feb 26, 2025 | $19.46 |
| Feb 27, 2025 | $19.43 |
| Feb 28, 2025 | $20.01 |
| Mar 03, 2025 | $19.29 |
| 4 days before | 7.66% |
| 4 days after | -4.08% |
| On release day | -3.23% |
| Change in period | 3.27% |
AxoGen Earnings Call Transcript Summary of Q4 2024
Financial Performance:
- Revenue: Full year revenue for 2024 reached $187.3 million, representing a 17.8% increase from 2023.
- Fourth Quarter Revenue: Total revenue for Q4 was $49.4 million, up 15.1% year-over-year.
- Growth Drivers: Positive performance was attributed to the successful adoption of Axogen's nerve repair algorithm across various clinical applications and markets.
Profitability:
- Gross Profit: For Q4, gross profit increased to $37.6 million, resulting in a gross margin of 76.1%.
- Net Income: The company reported a net income of $0.4 million for Q4, showcasing a turnaround from a net loss in the same quarter last year. Adjusted EBITDA for the quarter was $6.7 million.
Guidance for 2025:
- Revenue Growth Expectation: Axogen anticipates revenue growth of 15% to 17% for 2025.
- Gross Margin Expectation: Gross margin is expected to range between 73% and 75%, accounting for anticipated one-time costs related to the Biologics License Application (BLA) approval.
Strategic Priorities:
- New Market Opportunities: Introduction of a new strategic plan that identifies a total addressable market (TAM) of approximately $5 billion across various segments, including expansion into the prostatectomy nerve repair market.
- Focus Areas: Investments will be made in high-potential accounts and markets, standardizing the nerve repair algorithm as a standard of care in extremities, breast reconstruction through Resensation, and enhancing surgeon education for oral and maxillofacial procedures.
Regulatory Updates:
- BLA Approval: The BLA for Avance Nerve Graft was submitted in Q3 2024, with expectations set for approval in September 2025.
- Market Exclusivity: Avance is anticipated to receive designation as a reference product for future biosimilars, providing a 12-year exclusivity period.
Operational Enhancements:
- Sales Force Expansion: The company plans to double its sales team for its breast reconstruction segment and increase overall sales and marketing investments.
- Financial Strategies: Expected to remain cash flow positive throughout 2025, which will support the execution of its strategic plan.
Conclusion:
Investors should note Axogen's robust revenue growth and strategic initiatives aimed at expanding its market presence and enhancing profitability. The company displayed confidence in its financial outlook and emphasized its commitment to innovation and addressing emerging market opportunities. Future discussions at the upcoming Investor Day on March 4 will delve deeper into these strategies and growth projections.
AxoGen Earnings History
Earnings Calendar
FAQ
When is the earnings report for AXGN?
AxoGen (AXGN) has scheduled its earnings report for May 01, 2025 before the markets open.
What is the AXGN price-to-earnings (P/E) ratio?
AXGN P/E ratio as of Mar 14, 2025 (TTM) is -77.69.
What is the AXGN EPS forecast?
The forecasted EPS (Earnings Per Share) for AxoGen (AXGN) for the first fiscal quarter 2025 is -$0.0100.
What are AxoGen's retained earnings?
On its balance sheet, AxoGen reported retained earnings of $49.41 million for the latest quarter ending Dec 31, 2024.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
